Ultrasound-microbubbles mediated microRNA-449a inhibits lung cancer cell growth via the regulation of Notch1

doi:10.12092/j.issn.1009-2501.2019.12.011

Abstract

Abstract:

AIM: The application of gene-loaded microbubbles (MBs) combined with ultrasound that results in increased delivery efficiency, may be an excellent method of gene delivery. This study aimed to discuss effects of ultrasound-MB mediated microRNA (miR)-449a on lung cancer (LC) development by targeting Notch1. METHODS: Initially, miR-449a expression in LC tissues, paracancerous tissues, LC cell lines and lung epithelial cells was detected and its association with LC patients' clinical characteristics was analyzed. The gain-of function studies were performed to probe the roles of miR-449a and ultrasound-MB mediated miR-449a in LC progression. Then RT-qPCR combined with Western blot analysis was applied to verify the levels of miR-449a, Notch1, proliferation- and apoptosis-related proteins. RESULTS:Poorly expressed miR-449a was observed in LC. Overexpression of miR-449a suppressed LC cell proliferation, promoted G2/M arrest and apoptosis. Ultrasound-MB-mediated miR-449a strengthened inhibitory effects of miR-449a on cell growth and resistance to apoptosis. miR-449a inhibited H1299 cell activity by targeting Notch1. CONCLUSION: Our data supported that miR-449a overexpression inhibited LC cell growth, and ultrasound-MB-mediated miR-449a reinforced the repressive effects of miR-449a on LC progression. This investigation may offer new insight for LC treatment.

Key words: lung cancer, microRNA-449a, ultrasound-mediated microbubbles, Notch1

CLC Number:

R734
R965.2

ZHU Linjia, YUAN Shaofei, SHANGGUAN Zongxiao, CI Xiao, ZHAO Renguo, LI Yuping. Ultrasound-microbubbles mediated microRNA-449a inhibits lung cancer cell growth via the regulation of Notch1[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1385-1393.

References

［1］Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up［J］. Ann Oncol, 2014, 25 Suppl 3: 27-39.
［2］王海霞, 刘兴安, 侯继院, 等. KDR基因遗传变异对贝伐珠单抗一线治疗晚期非细胞肺癌患者临床疗效的影响［J］. 中国临床药理学与治疗学, 2018, 23(7): 802-808.
［3］Shen J, Liao J, Guarnera MA, et al. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis［J］. J Thorac Oncol, 2014, 9(1): 33-40.
［4］梅颖, 刘朝奇. miRNA调控肿瘤相关基因c-met的研究进展［J］. 中国临床药理学与治疗学, 2017, 22 (2): 204-209.
［5］Mercey O, Popa A, Cavard A, et al. Characterizing isomiR variants within the microRNA-34/449 family［J］. FEBS Lett, 2017, 591(5): 693-705.
［6］Luo W, Huang B, Li Z, et al. MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met［J］. PLoS One, 2013, 8(5): e64759.
［7］Ren XS, Yin MH, Zhang X, et al. Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells ［J］. Cancer Lett, 2014, 344(2): 195-203.
［8］Chen Y, Li D, Liu H, et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells［J］. Cancer Biol Ther, 2011, 11(1): 14-21.
［9］Yuan X, Wu H, Han N, et al. Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application［J］. J Hematol Oncol, 2014, 7: 87.
［10］Suzuki R, Oda Y, Utoguchi N, et al. Progress in the development of ultrasound-mediated gene delivery systems utilizing nano- and microbubbles ［J］. J Control Release, 2011, 149(1): 36-41.
［11］Wang DS, Panje C, Pysz MA, et al. Cationic versus neutral microbubbles for ultrasound-mediated gene delivery in cancer ［J］. Radiology, 2012, 264(3): 721-732.
［12］Shi ZM, Wang L, Shen H, et al. Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling ［J］. Oncogene, 2017, 36(18): 2577-2588.
［13］Guo XY, Lu M, Chen XQ, et al. Correlation study of biological characteristics of non-small cell lung cancer A549 cells after transfecting plasmid by microbubble ultrasound contrast agent［J］. Asian Pac J Trop Med, 2016, 9(6): 582-586.
［14］Ye W, Xue J, Zhang Q, et al. MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A［J］. Oncol Rep, 2014, 32(3): 1193-1199.
［15］You J, Zhang Y, Liu B, et al. MicroRNA-449a inhibits cell growth in lung cancer and regulates long noncoding RNA nuclear enriched abundant transcript 1［J］. Indian J Cancer, 2014, 51 Suppl 3: e77-81.
［16］Othman N, In LL, Harikrishna JA, et al. Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells［J］. PLoS One, 2013, 8(12): e81735.
［17］Xu P, Cai X, Zhang W, et al. Flavonoids of Rosa roxburghii Tratt exhibit radioprotection and anti-apoptosis properties via the Bcl-2(Ca(2+))/Caspase-3/PARP-1 pathway ［J］. Apoptosis, 2016, 21(10): 1125-1143.
［18］Hsu HY, Lin TY, Hu CH, et al. Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP activation to enhance cisplatin-induced cytotoxicity in human lung cancer cells ［J］. Cancer Lett, 2018, 432: 112-120.
［19］Quan X, Yin Z, Fang X, et al. Single nucleotide polymorphism rs3124599 in Notch1 is associated with the risk of lung cancer in northeast Chinese non-smoking females ［J］. Oncotarget, 2017, 8(19): 31180-31186.
［20］Capuano M, Iaffaldano L, Tinto N, et al. MicroRNA-449a overexpression, reduced NOTCH1 signals and scarce goblet cells characterize the small intestine of celiac patients［J］. PLoS One, 2011, 6(12): e29094.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[3]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[4]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[5]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[6]	SU Yang, ZHOU Feng, DING Jinlei. Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
[7]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[8]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[9]	WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei. Research progress on pathogenic fusion gene in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.
[10]	ZHAO Ziwen, FAN Fangtian, JIANG Zhijun. Induced bronchial associated lymphoid tissue (iBALT) formation and research of related lung diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 353-360.
[11]	CUI Hua, YAN Hongxia, YIN Mei. Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
[12]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[13]	PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
[14]	WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian. Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.
[15]	ZHAO Wei, WU Youyang, LIN Cong, HUANG Shiwei, CHEN Hao, JIANG Wenbing. Effects of pterostilbene on myocardial function, myocardial fibrosis and inflammatory response in rats with acute myocardial infarction and on Notch1/eIF3a signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 498-504.